FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development

A CDRH representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.